U.S. market Closed. Opens in 6 hours 5 minutes

BVS | Bioventus Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BVS we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak.

Valuation (36%)

Company Industry
P/E Ratio (TTM) -20.17 47.43
PEG Ratio (TTM) 0.23 -0.37
P/S Ratio (TTM) 1.60 6.17
P/B Ratio (TTM) 5.61 6.03
P/FCF Ratio (TTM) 131.39 41.68
Price to 5YR AVG Earnings Ratio -12.23 58.57
Price to 5YR AVG FCF Ratio 52.48 34.18

Profitability (3%)

Company Industry
ROA (TTM) -5.30% 5.30%
ROE (TTM) -24.93% 28.25%
Net Profit Margin (TTM) -7.82% 8.25%
ROIC 5YR AVG 1.99% 6.60%

Growth (45%)

4QTR AVG 3YR AVG 5YR AVG
EPS -118.10% 322.30% -255.93%
Revenue 3.16% 11.72% 10.81%
Net Income -120.46% 84.69% -409.04%
Cash Flow 47.38% -0.51% 10.59%

Health (18%)

Company Industry
Current Ratio (TTM) 1.33 2.90
Quick Ratio (TTM) 0.96 2.17
D/E Ratio (TTM) 2.56 0.61
Interest Coverage (TTM) 0.46 22.17
Piotroski F-Score 5 6
Altman Z-Score 1.00 7.62
LTL to 5YR AVG FCF 22.37 3.53
Shares Outstanding Growth 5YR AVG 2.42% 1.60%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙